I see these questions come up on social media, but they

New Post Public Reply Private Reply Replies (0) Message Board
redspeed
279
I see these questions come up on social media, but they have already been answered. For new investors, it may be helpful.

Why do the Tollovid trial in Israel?

"Every single company on the planet has been focused on getting data in Israel. They all laughed when we started because natural… as they have failed, no one laughing anymore. Data will come and focus is on its quality"

Why small trial size? Pfizer is so much larger?

When GC was, I guess told by an investor on twitter Jan. 1: "Going to be hard to show or have any kind of P value with just 30 patients"

GC responded also on New Years Day:
"Not in hospital setting. no. Outpatient I would agree. Everyone needs to understand fundamental difference , but showing benefit in hospital very bullish for outpatient."

For something like Covid where patients are dying in hospitals, you are not going to have a phase 2 with thousands in a few months. Show results that it reduced days in hospitals and also show the effectiveness with biomarkers and outpatient is unlimited potential. Or you can do like Pfizer and start with 'healthy' people first and just go after outpatient.

If Todos wants to do a pivotal 2/3, how long does that take?

Guess it would depend on whether Todos does inpatient or the easier path of outpatient like Pfizer

Pfizer outpatient went pretty quick from 1st participant in Sept to Interim data in November. 2 months


March 23, 2021 Pfizer Initiated Phase 1 Study of Novel Oral Antiviral Therapeutic Agent Against SARS-CoV-2. Phase 1 study was in HEALTHY adults to evaluate the safety, tolerability, and pharmacokinetics of the investigational compound.

September 1, 2021 Pfizer dosed the first participant in a pivotal Phase 2/3

The randomized, double-blind trial planned on enrolling approximately 1,140 participants, who received the drugs or placebo orally every 12 hours for five days.

November 5, 2021 Pfizer annouced their COVID-19 Oral Antiviral Treatment reduced risk of hospitalization or death by 89% in their interim analysis

December 22, 2021 Pfizer Receives U.S. FDA Emergency Use Authorization for Novel COVID-19 Oral Antiviral Treatment

What edge does Todos have over Pfizer's pills?

In addition to the anti-cytokine properties which I believe Pfizer's doesn't have and why they are went after out patient Paxlovid has side effects and their treatment has risks.

Q. Are there potential side effects of Paxlovid?
A. Possible side effects of Paxlovid include dysgeusia (altered or impaired sense of taste), diarrhea, increased blood pressure, and myalgia (muscle aches).
Nirmatrelvir and ritonavir, which comprise Paxlovid, also interact with other medicines, which may lead to serious or life-threatening adverse reactions. Patients should tell their health care providers all of the
medicines they are taking, including over-the-counter medications and herbal supplements, when deciding whether to take Paxlovid.
Liver problems have occurred in patients receiving ritonavir. Therefore, caution should be exercised when administering Paxlovid to patients with pre-existing liver diseases, liver enzyme abnormalities, or hepatitis. Patients should talk with their health care provider if they have a history of liver problems.

Paxlovid is not recommended for patients with severe kidney problems, and a different dose is needed for patients with moderate kidney problems. Patients should talk with their health care provider if they have a history of kidney problems.
Because nirmatrelvir is co-administered with ritonavir, there may be a risk of HIV-1 developing resistance to HIV protease inhibitors in individuals with uncontrolled or undiagnosed HIV-1 infection.
Patients with HIV who are not on treatment with “undetectable” viral load should talk with their health care provider before taking Paxlovid.
There are limited clinical data available for Paxlovid. Serious and unexpected adverse events may occur that have not been previously reported with Paxlovid use.

I heard Ivermectin has a 3CL protease inhibitor and it's cheap. Can't I load up on that to get the same effects of Paxlovid or Tollovid?

According to the company, you would have to take toxic levels to get close to the same level. Also neither of the other two have strong anti-cytokine activity.


Ivermectin Fans Have a New Champion to Root For - 3CL Protease Inhibitor Tollovid
https://www.zerohedge.com/news/2021-12-15/ive...r-tollovid



Todos Med Ltd. (TOMDF) Stock Research Links

TOMDF Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Job Market Shifts: Adaptation vs. Fairness Dilemma

Updated Category News Views 2

The Chameleon Effect in Today's Job Market Walk into any open-space office these days, and you'll see faces plastered with composed, work-ready smiles—faces that might not look so familiar outside those walls. The modern workplace has draped its cloak over individual personalities, with the mighty pressure to 'fit in' often forcing a change in how folks present...

Continue Reading
MCatalysis Secures $5M to Disrupt Fuel Cost Dynamics

Updated Category News Views 3

Funding Fuels Innovation MCatalysis has just secured a hefty $5 million in seed funding to throw down with the big dogs in energy production. This isn't your regular backyard science project; this company is serious about changing the game with a tech-driven approach that could undercut current fuel prices. HL Energy Ventures and Oxford Science Enterprises are backing...

Continue Reading
LeoLabs and SciTec Partner for $93.7M Space Force Deal

Updated Category News Views 1

LeoLabs and SciTec Join Forces for Space Dominance The space race ain't just about rockets blasting off anymore. It's about making sure we've got eyes everywhere, even on the back of our heads, so to speak. Enter LeoLabs teaming up with SciTec to help the U.S. Space Force upgrade their radar systems to something out of a sci-fi flick, armed with a $93.7 million contract...

Continue Reading
Cap Juluca: Caribbean Luxury Redefined on Maundays Bay

Updated Category News Views 0

The Tranquil Call of Maundays Bay Find me dipping my toes in the sands of Maundays Bay come October 10, 2026, and you'll understand why this slice of Anguilla stakes its claim to being the best beach on the globe. Cap Juluca, that crown jewel of Caribbean luxury, swings open its doors once more, promising indulgence framed by turquoise waters and the soft whisper of white...

Continue Reading
EFSI Shareholders on Alert Amid M&A Deal Scrutiny

Updated Category News Views 1

Eagle Financial Services Under the Microscope A buzz is picking up in the world of mergers and acquisitions, and this time, it's Eagle Financial Services, Inc. (NASDAQ: EFSI) caught in the crosshairs. What's the chatter all about? Well, it looks like Juan Monteverde and his crew over at Monteverde & Associates PC have set their sights on Eagle's proposed sale to John...

Continue Reading
CUBEX Lights Up Veterinary Care with Mini Essential

Updated Category News Views 5

Inventory Woes? Meet Mini Essential If you’ve ever worked in or around veterinary hospitals, you know the old-school headaches of managing controlled substances. Picture this: piles of paper logs, end-of-shift recounting, and inevitable discrepancies that rear their ugly heads long after closing time. Enter CUBEX, shaking things up with their latest launch, Mini...

Continue Reading
Midlife ADHD in Women: New Challenges and Solutions

Updated Category News Views 1

ADHD Evolution in Women's Midlife They say change is the only constant, and boy, does that ring true for women navigating the turbulent seas of ADHD as they hit 40 and beyond. According to Germaine Swanson, the ADHD landscape changes dramatically in midlife, especially for women. We're talking about a mix of hormonal shifts, increasing life demands, and changes in brain...

Continue Reading
Global Communication Works Opens SignlLabs™ AI Licensing

Updated Category News Views 29

AI Signaling Moves Beyond GCW's Own Clients Remember when we first looked at GCW's SignlLabs and the idea of helping brands show up inside ChatGPT, Gemini, Claude, Copilot and Perplexity? Well, Global Communication Works is taking the next step. Instead of keeping its AI Signaling playbook inside the agency walls, GCW is now opening SignlLabs up for licensing

Continue Reading
RARE Foundation Rebrands, Focus Still Strong

Updated Category News Views 1

Unveiling the RARE Foundation's New Identity In the stock market, you ride waves of change, and let me tell you, it ain't just stocks and bonds that change names and faces. Case in point: The EveryLife Foundation for Rare Diseases has spiffed up as the RARE Foundation. New name, new logo, the whole enchilada. This isn't just a cosmetic touch-up, though. It's about...

Continue Reading
Sacrifice Unending: 9/11's Lingering Health Toll

Updated Category News Views 0

The Unseen Toll of 9/11 on the Firefighter Community Two and a half decades since that fateful morning of September 11, 2001, we're staring at a grim reality. The heroic souls of the New York City Fire Department (FDNY)—those who ran toward peril when others ran away—are still paying the price. Incredibly, more than 400 FDNY members have succumbed to World Trade...

Continue Reading

Top 5 Most Recently Viewed Articles

Revolutionizing Cryptocurrency with ALR MINER's AI Cloud Service

Updated Category News Views 269

Revolutionizing Cryptocurrency Mining ALR MINER has emerged as a pioneering force in the cryptocurrency world by launching a groundbreaking zero-cost AI cloud mining platform. This innovative approach gives users the opportunity to earn cryptocurrencies like Bitcoin, Ethereum, Dogecoin, and Ripple without any upfront costs, reshaping the way mining is perceived and...

Continue Reading
Almost Heaven Saunas Joins Forces with Designing Spaces on TV

Updated Category News Views 109

Almost Heaven Saunas Unveils Exciting Collaboration Almost Heaven Saunas, the leading manufacturer of traditional saunas in the consumer market, has officially partnered with Designing Spaces on Lifetime TV. This collaboration emphasizes a shared commitment to enhancing health, wellness, and a deep-rooted connection with nature, values that resonate throughout the Harvia...

Continue Reading
SPX FLOW and Danone Team Up for Sustainable Growth Solutions

Updated Category News Views 91

SPX FLOW Teams Up with Danone for Sustainable Solutions SPX FLOW has signed a new partnership with Danone aimed at boosting Danone's focus on healthy and sustainable products, reinforcing the company's commitment to innovative practices. Goals of the Collaborative Partnership This collaboration will enhance Danone's production processes through the use of cutting-edge...

Continue Reading
CWST Earnings: What's Brewing for Casella Waste Systems?

Updated Category News Views 146

Casella Waste Sys (NASDAQ:CWST) is on the cusp of dropping its quarterly earnings this Thursday, February 19, 2026. Now, you know how these things work—it's not just about the numbers they throw at you but also about what happens next. And with analysts eyeing an earnings per share (EPS) of $0.22, all eyes are peeled to see if they can beat that and provide some glimmer...

Continue Reading
CME Group Unveils $2.1B Variable Dividend and $3B Repurchase

Updated Category News Views 184

CME Group Announces Major Shareholder Initiatives CME Group, recognized as the leading derivatives marketplace globally, has recently revealed important steps aimed at returning capital to its shareholders. Two major initiatives have been approved by the Board of Directors, highlighting the company's commitment to shareholder value. Annual Variable Dividend Details The...

Continue Reading